| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.8 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |